JAZZ Stock Analysis — Jazz Pharmaceuticals
Sector: Healthcare
AI Verdict
Jazz is cheap for the growth you're getting, but the market is skeptical that its orphan drug moat will protect earnings long-term.
Competitive Moat
Jazz Pharmaceuticals specializes in rare disease and neuroscience drugs, with a defensible position built on orphan drug exclusivity and a focused pipeline. Regulatory protections and limited competition in its core indications support above-average pricing power.
Summary
Jazz trades at just 8.3x next year's earnings, making it one of the cheapest names in specialty pharma with real revenue growth.
Where It Stands
With a forward P/E of 8.3x versus the healthcare sector median of 22x and trailing revenue growth of 9.2%, Jazz looks unusually cheap for a company still expanding its top line.
Key Metrics
- Forward P/E: 8.3x
- Revenue Growth: +0.1%
- 52-Week High: $230.40
- 52-Week Low: $97.56
Analyst Consensus
22 Buy · 2 Hold · 0 Sell (24 analysts)
Bull Case
The 8.3x forward P/E is less than half the sector median, while 9.2% revenue growth suggests the market is discounting the durability of its rare disease portfolio.
Bear Case
If Jazz's P/E were to re-rate down to 7x (closer to generic pharma multiples), the stock could see a further 15% downside even if earnings hold steady.
Catalyst to Watch
Watch for regulatory decisions or clinical trial readouts on pipeline drugs, as positive outcomes could justify the current valuation gap.